Clinical Trial Update: Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate [Phase 3]

View source ↗

Summary

A Phase 3 study compares overall survival in squamous cell carcinoma patients treated with INGN 201 versus methotrexate. The study status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma

Drugs mentioned

• INGN 201
• METHOTREXATE (METHOTREXATE)

Snippet

Sponsor: Introgen Therapeutics | Conditions: Carcinoma, Squamous Cell | Phase 3 | Status: UNKNOWN